Vol 9, No 6 (December 31, 2020) - Translational Lung Cancer Research

Editorial

Cyclin D1 expression in KRAS mutant non-small cell lung cancer—old wine into new skins

Kah Yee Goh, Wan-Teck Lim

PDF Pages: 2302-2304 Full Text (1491) COI Form Open Access

The gut microbiome and its interaction with health, disease, treatment response and toxicity in patients advanced cancer: focus on lung cancer and immunotherapy

Nadina Tinsley, Natalie Cook

PDF Pages: 2305-2307 Full Text (1284) COI Form Open Access

Radiomics signature for prediction of N2 disease: fascinating but still a long way to go for clinical application

Kwon Joong Na, Hongyoon Choi, Young Tae Kim

PDF Pages: 2308-2310 Full Text (824) COI Form Open Access

Current and future aspects of TIM-3 as biomarker or as potential targeted in non-small cell lung cancer scope: is there a role in clinical practice?

Ramon Andrade De Mello, Jin-Hui Zhu, Jairo Iavelberg, Artur Henrique Potim, Débora Simonetti, José Antônio Silva Jr, Pedro Castelo-Branco, Daniel Humberto Pozza, Carla Chizuru Tajima, Maria Tolia, Georgio Antoniou

PDF Pages: 2311-2314 Full Text (1485) COI Form Open Access

Original Article

Pre-radiotherapy lymphocyte count and platelet-to-lymphocyte ratio may improve survival prediction beyond clinical factors in limited stage small cell lung cancer: model development and validation

Yishan Yu, Linlin Wang, Shufen Cao, Siming Gao, Weili Wang, Lianne Mulvihill, Mitchell Machtay, Pingfu Fu, Jinming Yu, Feng-Ming (Spring) Kong

PDF Pages: 2315-2327 Full Text (2558) Reporting Checklist Data Sharing Statement COI Form Open Access

Stereotactic body radiotherapy for early stage non-small cell lung cancer in patients with subclinical interstitial lung disease

Yuanjun Liu, Yaoyao Zhu, Ran Wu, Min Hu, Lingnan Zhang, Qingren Lin, Denghu Weng, Xiaojiang Sun, Yu Liu, Yaping Xu

PDF Pages: 2328-2336 Full Text (2004) Reporting Checklist Data Sharing Statement COI Form Open Access

Metformin reverses chemoresistance in non-small cell lung cancer via accelerating ubiquitination-mediated degradation of Nrf2

Sha Huang, Tianyu He, Sijia Yang, Hongxu Sheng, Xiuwen Tang, Feichao Bao, Yiqing Wang, Xu Lin, Wenfeng Yu, Fei Cheng, Wang Lv, Jian Hu

PDF Pages: 2337-2355 Full Text (3073) Reporting Checklist Data Sharing Statement COI Form Open Access

Investigation on the potential of circulating tumor DNA methylation patterns as prognostic biomarkers for lung squamous cell carcinoma

Yutao Liu, Yu Feng, Ting Hou, Analyn Lizaso, Feng Xu, Puyuan Xing, Hongyu Wang, Qiaolin Kang, Lu Zhang, Yuankai Shi, Xingsheng Hu

PDF Pages: 2356-2366 Full Text (2330) Reporting Checklist Data Sharing Statement COI Form Open Access

Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy

Yanjun Xu, Hui Li, Zhiyu Huang, Kaiyan Chen, Xiaoqing Yu, Jiamin Sheng, Han-Han Zhang, Yun Fan

PDF Pages: 2367-2367 Full Text (3409) Reporting Checklist Data Sharing Statement COI Form Open Access

The feasibility of navigation bronchoscopy-guided pulmonary microcoil localization of small pulmonary nodules prior to thoracoscopic surgery

Junxiang Chen, Xufeng Pan, Chuanjia Gu, Xiaoxuan Zheng, Haibin Yuan, Jun Yang, Jiayuan Sun

PDF Pages: 2380-2390 Full Text (2033) Reporting Checklist Data Sharing Statement COI Form Open Access

Immunotherapy beyond progression in patients with advanced non-small cell lung cancer

Xiangwei Ge, Zhibo Zhang, Sujie Zhang, Fang Yuan, Fan Zhang, Xiang Yan, Xiao Han, Junxun Ma, Lijie Wang, Haitao Tao, Xiaoyan Li, Xiaoyu Zhi, Zhiyue Huang, Paul Hofman, Arsela Prelaj, Giuseppe Luigi Banna, Luciano Mutti, Yi Hu, Jinliang Wang

PDF Pages: 2391-2400 Full Text (4368) Reporting Checklist Data Sharing Statement COI Form Open Access

Survival benefit and toxicity profile of adjuvant icotinib for patients with EGFR mutation-positive non-small cell lung carcinoma: a retrospective study

Ziqing Zeng, Bo Yan, Yulong Chen, Lianmin Zhang, Jianquan Zhu, Fan Yang, Feng Wei, Terence Chi Chun Tam, Diego Kauffmann-Guerrero, Ross Andrew Soo, Xiubao Ren, Jian You

PDF Pages: 2401-2410 Full Text (5689) Reporting Checklist Data Sharing Statement COI Form Open Access

Hsa_circ_0006571 promotes spinal metastasis through sponging microRNA-138 to regulate sirtuin 1 expression in lung adenocarcinoma

Hou-Lei Wang, Hui-Ren Wang, Yun Liang, An-Nan Hu, Francisco J. Enguita, Xiao-Gang Zhou, Jian Dong

PDF Pages: 2411-2427 Full Text (2077) Reporting Checklist Data Sharing Statement COI Form Open Access

Whole exome sequencing (WES) analysis of transformed small cell lung cancer (SCLC) from lung adenocarcinoma (LUAD)

Tongji Xie, Yan Li, Jianming Ying, Weijing Cai, Junling Li, Kye Young Lee, Biagio Ricciuti, Jose Pacheco, Puyuan Xing

PDF Pages: 2428-2439 Full Text (4855) Reporting Checklist Data Sharing Statement COI Form Open Access

The protective effects of granulocyte-macrophage colony-stimulating factor against radiation-induced lung injury

Dan Hu, Yan Zhang, Ruiqi Cao, Yuying Hao, Xiaoye Yang, Tiantian Tian, Jiandong Zhang

PDF Pages: 2440-2459 Full Text (2580) Reporting Checklist Data Sharing Statement COI Form Open Access

Protocol

Treatment patterns, clinical outcomes, and healthcare resource use associated with advanced/metastatic lung cancer in China: protocol for a retrospective observational study

Bin Qiu, Gaofeng Li, Feng Luo, Xiaohong Cai, Lin Wu, Jianhua Chen, Yanping Hu, Zhiliu Tang, Shuo Yang, Jie He

PDF Pages: 2460-2468 Full Text (2095) COI Form Open Access

Review Article

A narrative review of progress in diagnosis and treatment of small cell lung cancer patients with hyponatremia

Ranpu Wu, Chuling Li, Zimu Wang, Hang Fan, Yong Song, Hongbing Liu

PDF Pages: 2469-2478 Full Text (3982) Reporting Checklist COI Form Open Access

A narrative review of evolving roles of radiotherapy in advanced non-small cell lung cancer: from palliative care to active player

Yue Zhou, Fan Yu, Yang Zhao, Ya Zeng, Xi Yang, Li Chu, Xiao Chu, Yida Li, Liqing Zou, Tiantian Guo, Zhengfei Zhu, Jianjiao Ni

PDF Pages: 2479-2493 Full Text (2934) Reporting Checklist COI Form Open Access

Case Report

Coexistence of a novel CCNY-ALK and ATIC-ALK double-fusion in one patient with ALK-positive NSCLC and response to crizotinib: a case report

Xuan Wu, Hanqiong Zhou, Zhen He, Zhe Zhang, Wen Feng, Jiuzhou Zhao, Haiyang Chen, Shuai Wang, Wei Wang, Qiming Wang

PDF Pages: 2494-2499 Full Text (3194) Reporting Checklist COI Form Open Access

A case report of exceptional clinical response to chemoradiotherapy and tyrosine kinase inhibitors in a patient with EML4-ALK fusion variant 1 non-small cell lung cancer

Xinyan Xu, Di Liu, Junmiao Wen, Jiayan Chen, Min Fan

PDF Pages: 2500-2507 Full Text (1564) Reporting Checklist COI Form Open Access

Editorial Commentary

Comment on “EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach”

Wickii T. Vigneswaran, Muaiad Kittaneh

PDF Pages: 2508-2510 Full Text (808) COI Form Open Access

Perspective of gene therapy with replication competent viruses

Makoto Maemondo

PDF Pages: 2511-2513 Full Text (1367) COI Form Open Access

Letter to the Editor

Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases

Tao Jiang, Xiaobo Xu, Xiaojuan Chen, Ning Ding, Qin Hu, Caicun Zhou, Jie Hu

PDF Pages: 2514-2517 Full Text (1646) Peer Review File COI Form Open Access

Editorial on Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions¹

Targeting chimeras fusion proteins in non-small cell lung cancer: where are we going?

Francesco Passiglia, Silvia Novello

PDF Pages: 2518-2520 Full Text (932) COI Form Open Access

Review Article on Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions¹

How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC)

Bing Xia, Misako Nagasaka, Viola W. Zhu, Sai-Hong Ignatius Ou, Ross A. Soo

PDF Pages: 2521-2534 Full Text (6529) Peer Review File COI Form Open Access

How selecting best therapy for metastatic NTRK fusion-positive non-small cell lung cancer?

Simon Ekman

PDF Pages: 2535-2544 Full Text (3848) Peer Review File COI Form Open Access

Resistance to anaplastic lymphoma kinase inhibitors: knowing the enemy is half the battle won

Fabrizio Tabbò, Maria Lucia Reale, Paolo Bironzo, Giorgio V. Scagliotti

PDF Pages: 2545-2556 Full Text (3073) COI Form Open Access

The role of plasma genotyping in ALK- and ROS1-rearranged lung cancer

Ibiayi Dagogo-Jack, Lauren L. Ritterhouse

PDF Pages: 2557-2570 Full Text (1966) COI Form Open Access

Decade in review: a new era for RET-rearranged lung cancers

Noura J. Choudhury, Alexander Drilon

PDF Pages: 2571-2580 Full Text (5540) COI Form Open Access

Overcoming TKI resistance in fusion-driven NSCLC: new generation inhibitors and rationale for combination strategies

Alessandro Russo, Andrés F. Cardona, Christian Caglevic, Paolo Manca, Alejandro Ruiz-Patiño, Oscar Arrieta, Christian Rolfo

PDF Pages: 2581-2598 Full Text (4639) COI Form Open Access

Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when?

Janna Josephus Anna Oda Schoenmaekers, Marthe Sentijna Paats, Anne-Marie Clasina Dingemans, Lizza Elisabeth Lucia Hendriks

PDF Pages: 2599-2617 Full Text (2364) COI Form Open Access

Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy

Kenichi Suda, Tetsuya Mitsudomi

PDF Pages: 2618-2628 Full Text (5495) COI Form Open Access

Future perspectives from lung cancer pre-clinical models: new treatments are coming?

Francesca Bersani, Deborah Morena, Francesca Picca, Alessandro Morotti, Fabrizio Tabbò, Paolo Bironzo, Luisella Righi, Riccardo Taulli

PDF Pages: 2629-2644 Full Text (2549) COI Form Open Access

Narrative review of molecular pathways of kinase fusions and diagnostic approaches for their detection in non-small cell lung carcinomas

Matthias S. Matter, Obinna Chijioke, Spasenija Savic, Lukas Bubendorf

PDF Pages: 2645-2655 Full Text (3002) Reporting Checklist Peer Review File COI Form Open Access

Integrating immune checkpoint inhibitors and targeted therapies in the treatment of early stage non-small cell lung cancer: a narrative review

Ana Ortega-Franco, Virginia Calvo, Fabio Franco, Mariano Provencio, Raffaele Califano

PDF Pages: 2656-2673 Full Text (3715) Reporting Checklist Peer Review File COI Form Open Access

Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer?—a literature review

Gianmarco Leone, Francesco Passiglia, Paolo Bironzo, Valentina Bertaglia, Silvia Novello

PDF Pages: 2674-2685 Full Text (2453) Reporting Checklist Peer Review File COI Form Open Access

How selecting best upfront therapy for metastatic disease?—Focus on ROS1-rearranged disease

Lorenza Landi, Federico Cappuzzo

PDF Pages: 2686-2695 Full Text (2286) Reporting Checklist COI Form Open Access

Consensus

Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer

Wenhua Liang, Kaican Cai, Chun Chen, Haiquan Chen, Qixun Chen, Junke Fu, Jian Hu, Tao Jiang, Wenjie Jiao, Shuben Li, Changhong Liu, Deruo Liu, Wei Liu, Yang Liu, Haitao Ma, Xiaojie Pan, Guibin Qiao, Hui Tian, Li Wei, Yi Zhang, Song Zhao, Xiaojing Zhao, Chengzhi Zhou, Yuming Zhu, Ran Zhong, Feng Li, Rafael Rosell, Mariano Provencio, Erminia Massarelli, Mara B. Antonoff, Toyoaki Hida, Marc de Perrot, Steven H. Lin, Massimo Di Maio, Antonio Rossi, Dirk De Ruysscher, Robert A. Ramirez, Wolfram C. M. Dempke, D. Ross Camidge, Nicolas Guibert, Raffaele Califano, Qi Wang, Shengxiang Ren, Caicun Zhou, Jianxing He

PDF Pages: 2696-2715 Full Text (15453) COI Form Open Access

Disclosure:

1. The series “Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions” was commissioned by the Editorial office, Translational Lung Cancer Research without any sponsorship or funding. Silvia Novello and Francesco Passiglia served as the unpaid Guest Editors for the series.

Vol 9, No 6 (December 31, 2020): Translational Lung Cancer Research